Tag Archives: IP

Innovation Act Threatens Biotech Innovation

AB23475

BIO has grave concerns regarding the Innovation Act (H.R. 3309), as reported by the House Judiciary Committee. The Innovation Act was introduced with the goal of furthering patent system reform, particularly with respect to patent-related litigation. We support increased transparency and oppose abusive litigation tactics. However, provisions in the Act remain overly broad in important respects and, if ultimately enacted, would continue to result in too many unintended and unknowable consequences for innovators who rely on the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

TRIPs Has Delivered: Patent Agreement Increases Drug Development

US Patent Application

The TRIPs (Trade Related Aspects of Intellectual Property) Agreement, effective in 1996, has resulted in multiple benefits for public health. The last blog post reviewed Progressive Economy’s finding of TRIPS at 20. One additional benefit not mentioned in the article is the explosion of molecules in clinical development. The World Intellectual Property Indicators – 2012 Edition reveals an overall growth in patent applications around the world. The report finds that patent applications “worldwide doubled from Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

Patents Improve Public Health: Progressive Economy Reviews TRIPS at 20 Years

flags with blue sky

Progressive Economy released a research paper examining the effect of TRIPS (Trade-Related Aspects of Intellectual Property) on global health. Here are their findings quoted from their press release: “1. Since the TRIPS agreement went into effect on New Year’s Day 1995, research and development spending has risen significantly worldwide (relative to the size of GDP). For OECD members, the rise is from 2.1 percent to 2.4 percent of GDP, or in practice an additional $220 Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Neglected Diseases: What if IP was the Cure?

Biopharmaceuticals and Accountable Care Organizations: Balancing Cost and Quality

The Lancet Global Health Journal recently published an article “The drug and vaccine landscape for neglected diseases (2000-11): a systematic assessment” discussing the current research and development ongoing in this area.  They found 1,500 clinical trials were registered for neglected diseases which represents only 1% of all registered clinical trial activity.  Of the 123 new products in development for neglected disease, more than half were vaccines or biological products.  However, the article points out that Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , ,

South Africa National Policy on Intellectual Property: Inconsistent with Biotech Development Goals

South-African-Flag

BIO submitted comments this week to the government of South Africa on their proposed “Draft National Policy on Intellectual Property.”  Below are some highlights. “BIO and its member companies are aware of the South African government’s aspirations to develop its life sciences industry, a message that South African officials communicated clearly at the recent BIO International Conference in Chicago, USA, in April 2013. At that conference and in subsequent discussions, South African officials have sent Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,